SCHEMBL3868040

SCHEMBL3868040

Cc1ccc(C(=O)NC[C@H](NC(=O)c2ccc(C(=O)NCc3cccc(O)c3)cc2Cl)C(=O)O)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.45
MT-CO2 P00403 1/20 0.43
ITGB1 P05556 2/20 0.43
ITGA4 P13612 2/20 0.43
PPARG P37231 3/20 0.43
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.40
ITGAL P20701 1/20 0.40
ITGB7 P26010 1/20 0.39
S1PR1 P21453 1/20 0.39
CTSB P07858 1/20 0.39
RAB9A P51151 1/20 0.39
GRN P28799 1/20 0.39
SORT1 Q99523 1/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
PYGL P06737 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872577 0.94 MT-CO2 (0.43) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3876648 0.93 ITGB1 (0.47) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3868188 0.92 MT-CO2 (0.42) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3873251 0.92 ALDH1A1 (0.44) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3870373 0.92 PPARG (0.46) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3866004 0.92 ITGB1 (0.46) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3868304 0.91 MT-CO2 (0.48) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3873044 0.91 PPARG (0.49) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL3871876 0.91 PPARG (0.45) NR1H4MT-CO2ITGB1ITGA4PPARG
SCHEMBL12361222 0.91 ROCK2 (0.47) NR1H4MT-CO2ITGB1ITGA4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US claimed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US claimed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US claimed
US-7491741-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-17 US disclosed
US-20070155671-A1 Diaminopropionic acid derivatives FOTOUHI NADER 2007-07-05 US disclosed
US-7217728-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2007-05-15 US disclosed
US-20050080119-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2005-04-14 US disclosed
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US disclosed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US disclosed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006236-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A NR1H4 564/4885MT-CO2 1844/4885ITGB1 1498/4885
US-20020052512-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A NR1H4 564/4885MT-CO2 1844/4885ITGB1 1498/4885
US-20070155671-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 NR1H4 490/4885MT-CO2 1431/4885ITGB1 1894/4885
US-20050080119-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 NR1H4 490/4885MT-CO2 1431/4885ITGB1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.